We propose to analyse the long-term follow-up in patients older than 65 years of age who received a mechanical valve in the aortic position, using death and prosthetic-related complications as endpoints. From April 1988 to December 1995, 144 consecutive patients 65-75 years of age (mean 67.7"2.5) were enrolled. Total duration of follow-up was 1663 patient-years (median 13.0 years) and was complete for 99% of the patients. Thirty-day mortality was 1.4% (ns2). At the end of the study, 77 patients (53.8%) were alive, with ages ranging from 77 to 91 years (mean 82.1"3.2 years). The overall 5-, 10-and 15-year actuarial survival was 87.4%"3.0, 67.7%"4.3 and 58.5%"4.5, respectively. Freedom from stroke was 93.3"3.1%, 84.6"3.3% and 71.7"4.5%, respectively, after identical periods. Freedom from major bleeding was 97.2"1.1%, 90.4"3.5% and 86.4"4.0%, respectively. Freedom from endocarditis was 95.7"2.3%, 95.0"2.1% and 94.4"2.5%, respectively, and freedom from reoperation was 98.0"1.2%, 97.6"1.3%, 96.9"2.4% and 96.4"2.6%, respectively. Freedom from major valve-related events was 87.7"2.6%, 73.9"3.4% and 61.5"4.6%, respectively. Nearly two-thirds of the patients were alive and free from major adverse valve-related events. Hence, we consider implantation of a mechanical prosthesis in elderly patients safe and appropriate, but the choice must be tailored for each specific patient.
Introduction
There is no perfect valve substitute. All prostheses, whether mechanical or biological, involve some compromise and all introduce a new disease process, the prosthetic disease. Considerations for choosing between a mechanical valve and a bioprosthesis concern haemodynamic performance, long-term durability and the need for chronic anticoagulation.
Currently in Europe and in the USA, there are trends towards increasing the use of tissue valves, in progressively younger patients w1-3x, probably supported by reports of very low rates of bioprosthetic failure in elderly patients w4, 5x, particularly with the newer models w6x.
Although there are several studies addressing the behaviour of mechanical valves in the elderly patients, only a few have long follow-up analysis concerning survival and valve-related events w7-10x. In the present study, we analyse early and late survival, adverse valve-related events and the quality of life in this specific patient population (65-75 years), in a follow-up of up to 20 years.
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Material and methods

Patient population
From April 1988 to December 1995, a total of 144 consecutive patients aged 65-75 years (mean 67.7"2.5 years), 93 males (64.6%), underwent aortic valve replacement (AVR) with a mechanical prosthesis. Patients receiving concomitant coronary artery bypass surgery (CABG) and other surgical procedures were included. The time interval for inclusion in this study was determined to permit at least a 12-year period of follow-up.
During the same time interval, we also implanted 102 bioprostheses in patients of this age group. The initial design of the work was a comparative study between the two types of valves, but patients in the biological valve group were significantly older, with more co-morbidities, which precluded an accurate comparison.
Preoperatively, 87 patients (60.4%) were in NYHA (New York Heart Association) class III or IV, 28 (19.4%) had left ventricular dysfunction (ejection fraction -45%) and 30 (20.8%) were in chronic atrial fibrillation. Table 1 summarizes the baseline demographic and clinical characteristics of the patients.
Surgical indications for AVR were: stenosis (ns101, 70.1%), insufficiency (ns40, 27.8%) and endocarditis (ns3, 2.1%), including one case of aortic prosthetic endocarditis. Five cases were re-operative cardiac interventions (3.5%).
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Operative technique and data
The operative technique was standardized for all patients and included cardiopulmonary bypass with moderate hypothermia (28-308), topical cooling with ice slush in the pericardium and intermittent antegrade cold crystalloid cardioplegia, either in the aortic root or directly in the coronary ostia.
Only two types of aortic prostheses were implanted, Medtronic-Hall (Medtronic Inc, Minneapolis, MN, USA) and Carbomedics (Sulzer Medica, Austin, TX, USA), both considered to have low thrombogenicity w11x.
Concomitant procedures were performed in 39 patients (27%), the most frequent being CABG and mitral valve repair ( Table 1) .
Anticoagulant management
Anticoagulation was initiated with warfarin on the first or second postoperative day, depending on the patient's condition. During the initial years of this experience, the prothrombin time or index were used to monitor the level of anticoagulation, with a target prothrombin time ratio of 1.5-2. More recently, the international normalized ratio (INR) has been used to monitor the level of anticoagulation with a target of 2.0-3.0 units. Control of the prothrombin time or the INR after discharge from the hospital was done by the patient's physician, after initial stabilization by the surgeons (all patients had a blood sample drawn for anticoagulation control at the time of the last postoperative visit, usually at 1 month).
Data collection, follow-up and outcome events
Perioperative data were obtained by review of the patient's hospital records, catheterization reports, cineangiograms and echocardiography. Follow-up information was collected during a 3-month period (cross-sectional mode), closing end of January 2008. This was done through a mailed questionnaire or by telephone interview with surviving patients, family members or the patient's physician. Follow-up data included information about activity level, current symptoms, occurrence of late cardiac and noncardiac events, regularity of anticoagulation control and if the INR value was in the target range.
The total duration of follow-up for the entire cohort was 1663 patient-years (range 0-19.1 years, median 13.0 years (interquartile range 9.1-14.6 years) and was complete for 99% of the patients (one patient lost for follow-up).
Prosthetic-related complications were recorded according to the 2008 Guidelines for Reporting Mortality and Morbidity after Cardiac Valve Interventions w12x. Major adverse valverelated events (MAVE) included: valve-related mortality (sudden, unexplained death included); all valve-related morbidity and need for new permanent pacemaker or defibrillator within 14 days after the valve intervention.
Statistical analysis
Data were presented as frequency distributions and simple percentages. Continuous variables were expressed as mean" standard deviation (S.D.). Patient survival was calculated by actuarial analysis according to the Kaplan-Meier method, using time zero as the date of operation and late death as the end point (with variability expressed as standard error of mean). Linearised rates of occurrence for selected events were calculated and expressed as % per patientyear (pt-yr). Data were analysed using the SPSS software package (SPSS, Inc, Chicago, Illinois, USA).
Results
Hospital mortality and morbidity
There was only one hospital death (0.7%), due to aortic rupture in the first postoperative day. The patient was reopened in extremis in the ICU, but it was not possible to control the bleeding. One patient died from sudden death two weeks after discharge (30-day mortality, 1.4%).
One-third of the patients (33.3%), experienced some type of postoperative morbidity, the most frequent being rhythm disturbances (atrial fibrillationyflutter, complete AV block), followed by acute renal failure (creatinine )2 mgydl) and respiratory complications (infectious, pneumothorax, pleural effusion) ( Table 2) . Most episodes were minor and easily controlled.
The mean length of hospital stay was 9"2.1 days. CVA, cerebro-vascular accident. 
Late mortality
During the course of this 20-year study, 66 patients died (45.8%). Nearly half of the deaths were non-cardiac, malignancies representing a major cause. There were 31 cardiac deaths (46.9%) and only 14 of those were valve-related (21.2%). Stroke was the most frequent cause of valverelated mortality, followed by prosthetic endocarditis and sudden death. The causes of late death are listed in Table 3 .
At the completion of this study, 77 patients (53.8%) were alive, with ages ranging from 77 to 91 years (mean 82.1" 3.2 years). Fig. 1 displays the long-term actuarial survival of the patients. The overall 1-, 5-, 10-and 15-year actuarial survival was 95.1%"2.1, 87.4%"3.0, 67.7%"4.3 and 58.5%" 4.5, respectively. When the study population was subdivided in subgroups by age (65-69 years vs. 70-75 years), or according to associated procedures performed, there were no statistical differences regarding overall survival.
Valve-related events
Thromboembolism and major bleeding
Twenty-six patients (18.0%) experienced a neurological event (CVAyTIA), which was fatal in seven. Five patients who survived a stroke episode remained with some degree of disability, the others recovered fully. Two patients had more than one episode of thromboembolism. One-, 5-, 10-and 15-year freedom from stroke ( Fig. 2a) was 96.1"2.2%, 93.3"3.1%, 84.6"3.3% and 71.7"4.5%, respectively. The linearised incidence was 1.56%ypt-yr.
Fourteen patients (9.7%) suffered a major haemorrhage and one patient died from a spontaneous acute subdural haematoma. One-, 5-, 10-and 15-year freedom from major bleeding was 99.1"1.2%, 97.2"1.1%, 90.4"3.5% and 86.4"4.0%, respectively (Fig. 2b) . The rate of occurrence was 0.84%ypt-yr.
The linearised incidence of the composite outcome thromboembolism plus major bleeding was 2.4%ypt-yr.
Endocarditis and reoperation
Eight patients (5.5%) had prosthetic endocarditis, three underwent surgery and the remaining were treated medically. Three patients died from the event.
Five patients (3.5%) were subjected to at least one reintervention, three because of prosthetic endocarditis, one for paravalvular leak and one for nonstructural dysfunction (entrapment by pannus). Two patients had more than one reoperation (endocarditis).
One-, 5-, 10-and 15-year freedom from endocarditis was 96.4"1.6%, 95.7"2.3%, 95.0"2.1% and 94.4"2.5%, respectively (Fig. 3a) , and freedom from reoperation was 98.0"1.2%, 97.6"1.3%, 96.9"2.4% and 96.4"2.6%, respectively (Fig. 3b) . The linearised incidences of endocarditis and reoperation were 0.48%ypt-yr and 0.3%ypt-yr, respectively.
Major adverse valve-related events (MAVE)
Forty-one patients (28.5%) experienced at least one important adverse valve-related event. In 14 patients, it resulted in death, which means that nearly two-thirds of the patients outlived the adverse event.
One-, 5-, 10-and 15-year freedom from MAVE was 92.8" 1.0%, 87.7"2.6%, 73.9"3.4% and 61.5"4.6%, respectively (Fig. 4) . MAVE occurred at a linearised rate of 2.5%y pt-yr. 
Discussion
Our policy regarding AVR is to implant a mechanical prosthesis in every 'suitable' patient until 70-72 years of age. The 'suitability' is determined by a comprehensive conversation, firstly with the cardiologist and nurse who received the patient and secondly with the cardiac surgeon, with the patient.
One particularity of this study is the long follow-up for this patient population, with a mean follow-up time of 11.7"4.3 years and maximum of 19.1 years. At the completion of this study more than half of the patients were alive, with ages ranging from 77 to 91 years (mean 82.1"3.2), which probably would have placed some of them at risk of reoperation for structural valve deterioration, if a bioprosthesis had been implanted.
The overall 10-and 15-year actuarial survival of our patients was 67.7% and 58.5%, respectively, which is, in our opinion, remarkable for this specific patient population. It is important to emphasize that only half of the late deaths were from cardiac causes and only about one-fifth were valve-related, including three suddenyunexplained deaths, meaning that freedom from cardiac and valverelated mortality was significantly better than the overall survival observed. There was no significant difference when comparing the overall survival of this cohort of patients to the life expectancy of the general population above 65 years of age (Institute of National Statistics; 16.9 vs. 17.9 years).
The fact that 18% of the patients suffered from at least one episode of thromboembolism would appear to be a high risk, but the linearised incidence (1.56%ypt-yr) is perfectly admissible, notwithstanding the fact that thromboembolism also occurs with bioprostheses. Nevertheless, it can be assumed that this percentage could be overestimated because all the episodes of CVAyTIA were classified as valve-related events and in most of them there was no echocardiographic information regarding the valve status, including the presence of thrombus. Furthermore, this specific population is also susceptible to central neurological events from other sources, such as aortic, carotid and vertebral artery disease. We observed a lower rate of major bleeding events (0.84%ypt-yr), compared to others w13, 14x, but higher than that reported in recent papers from Vicchio and colleagues w15x who had a 5-and 10-year freedom from bleeding of 98.7% and 98.3%, respectively. We believe that this low incidence of significant haemorrhage is partially due to patient selection (good compliance to anticoagulation therapy), to intensive nurse-patient education during hospitalization, explaining the necessity and risks of taking anticoagulants, and, perhaps, to an aggressive follow-up by the surgeons in the first months after discharge. In addition, levels of anticoagulation were kept marginally lower than those we use in younger patients. Naturally, this may have had an impact in the incidence of thromboembolism.
As expected, prosthetic endocarditis was a fearful event, with almost half of patients who experienced it dying as a consequence. Only three patients who had endocarditis are still alive and they were all treated conservatively.
Other reinterventions because of the aortic prosthesis were rare, consistent with other results in the literature, with 10-and 15-year freedom from reoperation of 96.9" 2.4% and 96.4"2.6%, respectively, which is certainly lower than those usually described for bioprostheses after identical follow-up periods, even in this age group w4, 5x.
There are several limitations of this study. Firstly, it is retrospective and the patients subject to selection bias, although the decision to use a mechanical valve was collegial and not by individual surgeons, which assured consistency. Because it represents a cross-sectional follow-up, data on valve-related complications were not collected on an ongoing basis. We tried to minimize this by a thorough search for adverse events and review of all the clinical files available looking for events that required hospitalization. Secondly, a comparison with a similar group of elderly patients undergoing bioprosthetic implantation would be of extreme value. But our selection criteria for mechanical valves precluded such comparison. Only a randomised study could solve this issue.
At the end of the study, about two-thirds of our patients were alive and free from MAVE. Hence, we consider implantation of a mechanical prosthesis in elderly patients safe and appropriate, but consider that the choice must be tailored for each specific patient. Biologic valves are considered the optimal choice in patients older than 65 years by the American College of Cardiology/American Heart Association 2008 guidelines w3x. Mechanical AVR has still some reservations to offer, because it may be associated with complications, such as anticoagulation and thromboembolism. However, the choice of mechanical prosthesis in the elderly patients often depends on different factors, including chronic atrial fibrillation, the use of anticoagulation for other diseases, less need of re-operation, preference of the cardiologist or surgeon as well as patients' wishes, and technical reasons related to aortic annulus. We recently reported a cohort of patients who underwent aortic valve replacement and coronary artery bypass surgery w4x. We did not find any differences between the two types of prosthesis. Which mechanisms were responsible for neurological injury in patients who received mechanical valve prosthesis is obscure. Central neurological events may be due to not only the valve itself but also to other causes, such as aortic, particularly carotid and vertebral artery disease in this older age group. Furthermore, many patients are prone to cerebrovascular events at the advanced age. So, what is the explanation for this finding? Does the mechanical valve, whether from the valve itself or from its associated anticoagulation, in the elderly patient really have some advantages? A randomized prospective trial of mechanical vs. biological valves would answer the question.
The controversial aspect of this article is that the authors presented only patients who received a mechanical valve with excellent survival. It would be better to compare them with those who received a tissue valve. We would like to congratulate the authors for their excellent long-term results with an acceptable mortality and morbidity rate.
